Rapport Therapeutics RAPP 深 滬
交易中 08-21 10:03:25 美东时间
47.93
+0.080
+0.17%
華盛通- 最 高48.36
- 今 開48.36
- 成交量 1.48万股
- 最 低 47.93
- 昨 收 47.85
- 總市值 23.00亿
- 52周最高 49.90
- 市盈率 靜 --
- 換手率 0.03%
- 52周最低 14.11
- 委 比 -68.90%
- 總股本 4797.83万
- 歷史最高 49.90
- 量 比 1.41
- 振 幅 0.90%
- 歷史最低 6.43
- 每 手 1
- 風險率 7.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $66
HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $40 to $66.
08-13 00:58
Rapport Therapeutics reports Q2 results
Rapport Therapeutics press release (RAPP): Q2 net Loss was $56.6M, as compared to $26.7M for the prior year period. RAPP expects that cash, cash equivalents, and short-term investments as of June 30, ...
08-06 02:21
Rapport Therapeutics Q2 EPS $(1.19) Misses $(0.96) Estimate
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(1.19) per share which missed the analyst consensus estimate of $(0.96) by 23.96 percent. This is a 58.67 percent decrease over losses of $(0.75) per share from the same period last year.
08-05 19:24
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
Rapport Therapeutics reported Q2 2026 financial results and highlighted progress in its RAP-219 epilepsy program, including initiation of Phase 3 trials for focal onset seizures and bipolar mania trials on track for October 2026 results. The company also advanced its pipeline with RAP-219 long-acting injectable and RAP-641 programs. Cash reserves of $436.1 million are expected to fund operations into 2029. RAP-219's Phase 2a data showed significa...
08-05 11:00
美股大行评级 | 阿斯麦、贝莱德、纽约梅隆银行、信达思、JB亨特运输服务、美国制商银行、PNC金融服务集团等获多家大行集体上调目标价
今日重点评级关注：瑞杰金融：维持Electrovaya"强力买入"评级，目标价从14美元升至22美元；BTIG：维持vTv Therapeutics"买入"评级，目标价从49美元升至57美元
07-17 11:35
BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.
07-16 17:49
美股大行评级 | 瑞银上调超微公司目标价从455美元升至670美元，上调ARM目标价从260美元升至470美元；美银证券上调台积电目标价从490美元升至590美元
今日重点评级关注：Jones Trading：维持Definium Therapeutics"买入"评级，目标价从61美元升至74美元；韦德布什：维持Cerebras Systems"跑赢大市"评级，目标价从270美元升至280美元
06-25 11:32
Leerink Partners Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price Target of $52
Leerink Partners analyst Marc Goodman initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Outperform rating and announces Price Target of $52.
06-25 02:41
